Overall verdict
Neutral
6.4/10
1-year performance
+43.01%
Score breakdown
Up 43.0% over 1 year, 79% of the 52-week range.
Strongest: Profitability 7.1/10. Weakest: Financial strength 4.2/10.
34 analysts, target -0.0% vs the price.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis ; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease ; Prolia to treat postmenopausal women with osteoporosis ;
XGEVA for skeletal-related events prevention ; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization ; Nplate for the treatment of patients with immune thrombocytopenia ; KYPROLIS to treat patients with relapsed or refractory multiple myeloma ; Aranesp to treat a lower-than-normal number of red blood cells and anemia ; EVENITY for the treatment of osteoporosis in postmenopausal for women ;
Vectibix to treat patients with wild-type RAS metastatic colorectal cancer ; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia ; TEPEZZA to treat thyroid eye disease ; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI.
The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE ; BEONE MEDICINES LTD. to develop and commercialize Aimovig ; UCB for the development and commercialization of EVENITY ;
Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization ; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Robert Bradway
Founded
1980
Employees
31 500
Revenue / employee
1.2M USD
Next earnings
November 5, 2026 (estimated)
Institutional holders
- BlackRock, Inc.9.20%
- VANGUARD CAPITAL MANAGEMENT LLC6.57%
- STATE STREET CORP5.70%
- Capital World Investors5.42%
- Invesco Ltd.3.04%
- GEODE CAPITAL MANAGEMENT, LLC2.93%
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.80%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.77%
- MORGAN STANLEY2.55%
- Other institutions42.67%
- Rest of the register16.35%
3144 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
447.03 USD
52-week low
269.77 USD
1-year performance
43.01%
Rising
Year-to-date performance
23.52%
Rising
Drawdown
-8.44%
Mild pullback
Position in the 52-week range
79% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 1.9 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Amgen | 134 435 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-29 % between November 2022 and June 2023. 10,000 € placed at the top fell to 7 051 €. The world ETF, at worst: -34 %. Back to its high in 7 months.
Amgen earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Amgen: 134 435 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 352.39 USD - 370.94 USD (3 methods agree)
The price implies growth of 5.99% per year; the company grows at 2.93%.
Gross margin 72.7%, net margin 22.9%, ROIC 14.0%, ROE 91.5%.
Net margin
22.89%
High
Sector -15.62%|S&P 12.97%
Gross margin
72.71%
Fair
Return on equity (ROE)
91.47%
Exceptional
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
14.02%
Fair
Free cash flow margin (FCF)
26.63%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.16x
High
Margin stability
8.5 pts
Uneven
Revenue to net income
Growth
6.4/10Revenue up 9.8% over 1 year, 7.8% a year over 5, EPS 2.9% a year over 5.
Revenue (trailing 12 months)
38.2Md USD
Revenue growth (1y)
9.82%
Solid
Revenue growth (3y)
40.81%
Solid
EPS growth (1y)
64.93%
Hyper-growth
EPS CAGR (5y)
2.93%
Low
EPS revisions (3 months)
2.98%
Revised up
Valuation
5.8/10P/E 25.4x, forward P/E 25.9x, EV/EBITDA 16.3x, PEG 8.67. The multiple sits in the 79th percentile of its own 5-year history.
P/E (TTM)
25.4x
Fair
Sector 29.9x|S&P 23.0x
Forward P/E
25.9x
Fair
EV / EBITDA
16.3x
Fair
Sector 23.4x|S&P 14.5x
PEG
8.67
Very expensive
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
361.67 USD
Overvalued
P/E vs its own 5-year history
among the 21% highest valuations
Pricier than usual
Market cap
220Md USD
Financial strength
4.2/10Cash covers 24.4% of the debt, net debt/EBITDA 2.9x.
Net debt / EBITDA
2.9x
Stretched
Gearing (net debt / equity)
370.59%
Stretched
Cash
14.0Md USD
Cash / market cap
6.37%
Tight
Cash / total debt
24.41%
Tight
Interest coverage
4.3x
Tight
Net debt
43.3Md USD
Equity
11.7Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 406.04 USD
- MM20406.02
- MM50403.84
- MM200361.66
- RSI 1451.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.11%
200-day average slope, 3 months
+8.53%
50-day average slope, 1 month
+5.58%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.70 % per day
Volatility change
+62.42%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 15.83 (13) | 23.06 (33) | 38 938 (31) | 21 864 (5) | 8 581 (12) |
| 2027 | 17.67 (13) | 24.45 (33) | 40 309 (31) | 22 213 (5) | 9 393 (12) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.4 | 6.0 | 220Md USD | 25.4x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 43.0 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
